Our Main Goal

We bridge engineering and biology to advance the development
of new biopharmaceuticals.

Bioengineering for Cell-based Therapies

Advanced Technologies for Gene Therapy Products

Advanced Cell Models for Drug Discovery and Translational Research

Translational Immunology

Protein Biophysics for Drug Discovery

Vaccines Bioprocess Engineering

Biopharma

Natural Bioactives & Nutraceuticals

Microbiology and Molecular Biology

Sustainability for Food & Health
For Partners

We create value by leveraging our scientific and technological knowledge in Biology and Engineering. We develop improved and innovative bioprocesses, products and analytical tools. We work to maximize knowledge transfer between academia and industry.

>150

R&D projects with industry partners

For Scientists

We employ, train, and develop interdisciplinary and creative scientists to work at the interface between technological development and tech transfer. We offer cutting-edge infrastructure for biotechnology research. We fund original ideas from early-career scientists through iBETXplore innovation program.

110

PhD holders and over 40 PhD students distinguish our highly qualified research community

Right now we are developing
a next-generation vaccine against malaria.

Our scientists are producing
heart cells to build an artificial ventricle.

We are culturing mini-brain tumours to help companies
test ground-breaking anti-cancer therapies.

  • news
  • publications
News

iBET’s Affiliated Research Units Renew the FCT Seal of “Excellent”
April 17, 2025
Awards

CEO Paula Alves Honored with APIFARMA’s Merit Personality Award
November 28, 2024
Awards We are iBET

Professor Manuel Carrondo distinguished with Medal of Scientific Merit by FCT
July 11, 2024

Billion‐Scale Expansion of Functional hiPSC‐Derived Cardiomyocytes in Bioreactors Through Oxygen Control and Continuous Wnt Activation
Advanced Science
Publication 2025

Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors
Biotechnology and Bioengineering
Publication 2025

Beyond guaiacol and halophenols: Unravelling isobutyric and isovaleric acids as new culprits in off-flavour spoilage by Alicyclobacillus spp.
International Journal of Food Microbiology
Publication 2025

MoA Studies of the TEAD P-Site Binding Ligand MSC-4106 and Its Optimization to TEAD1-Selective Amide M3686
Journal of Medicinal Chemistry
Publication 2024

iBET in Numbers

270

iBET staff working on biotech solutions of tomorrow

60

State-of-the-art R&D labs equipped with the latest cell culture and bioanalytical equipment

90

Public and privately funded ongoing R&D projects

>400

Peer-reviewed publications in the last 5 years

3.5 M€

Invested in internal innovation through our iBETXplore Program
Interested in working together?

Contact us
Manuel Carrondo

    At iBET, we work at the forefront of ATMPs and vaccine technologies to deliver the best value to our partners.

    Paula Alves

    iBET CEO

    iBET, committed to excellence for Biopharmaceuticals research and development.

    Manuel Carrondo

    iBET Vice President

    Jobs and Training

    MSc and PhD Training

    At iBET you will find a truly interdisciplinary team (engineers, biologists, biochemists, data scientists) plus cutting-edge research facilities to pursue your academic research training in Biotechnology and Life Sciences. Our focus on applied research and knowledge transfer to industry offers you a unique setting to broaden your career perspectives in close contact to the job market.

    Learn more
    Job Offers
    Careers

    Join an interdisciplinary and agile team driven by ambition, commitment, and innovation. With a focus on technological progress, continuous improvement, and career development, we offer continuous growth opportunities. Come be part of our mission to provide biotech solutions to our industry partners.

    Learn more